News & Stories from the Rogel Cancer Center

How genetic testing and family history help identify individuals at high risk for pancreatic cancer, enabling earlier screening and better treatment outcomes.

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.

Michigan mom had no reason to suspect cancer. But instinct nudged her to find out for sure — and carried her through challenging treatments to remission.

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.

New study from researchers at the University of Michigan Rogel Cancer Center showed an online resource and phone-based coaching both helped increase rates of genetic testing.

Two U-M Researchers Earn Election to National Academy of Medicine

Two research papers describe how long-read nanopore sequencing can detect alterations in cancer cells that might be missed by conventional sequencing.

University of Michigan researchers found a new protein target PP2A and developed a drug to treat non-small cell lung cancers that have KRAS mutations.

U-M Health Rogel Cancer Center used single-dose immunotherapy and transplant oncology to treat advanced hepatocellular carcinoma in a 69-year-old patient.

FDA-approved rusfertide offers new hope for polycythemia vera patients by reducing phlebotomy dependence, easing symptoms, and improving daily life.

When 18-month-old Maria was diagnosed with an exceptionally rare kidney cancer, specialists at C.S. Mott Children's Hospital created a customized treatment plan that saved her life.

University of Michigan researchers discovered a new pathway that sensitizes mIDH1 gliomas to radiation in human and mouse mIDH1 glioma cells and mouse models, paving the way for phase 1 clinical trials in humans